NGNE Stock Overview
A biotechnology company, develops genetic medicines for rare neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Neurogene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.30 |
| 52 Week High | US$74.49 |
| 52 Week Low | US$12.49 |
| Beta | 0 |
| 11 Month Change | -58.03% |
| 3 Month Change | -44.76% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 34.44% |
Recent News & Updates
Shareholder Returns
| NGNE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -41.2% | 2.5% | 2.2% |
| 1Y | n/a | 16.1% | 31.6% |
Return vs Industry: Insufficient data to determine how NGNE performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how NGNE performed against the US Market.
Price Volatility
| NGNE volatility | |
|---|---|
| NGNE Average Weekly Movement | 25.1% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NGNE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NGNE's weekly volatility has increased from 17% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 91 | Rachel McMinn | www.neurogene.com |
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC.
Neurogene Inc. Fundamentals Summary
| NGNE fundamental statistics | |
|---|---|
| Market cap | US$301.02m |
| Earnings (TTM) | -US$3.28m |
| Revenue (TTM) | US$925.00k |
325.4x
P/S Ratio-91.9x
P/E RatioIs NGNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGNE income statement (TTM) | |
|---|---|
| Revenue | US$925.00k |
| Cost of Revenue | US$57.65m |
| Gross Profit | -US$56.73m |
| Other Expenses | -US$53.45m |
| Earnings | -US$3.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | -6,132.86% |
| Net Profit Margin | -354.16% |
| Debt/Equity Ratio | 0% |
How did NGNE perform over the long term?
See historical performance and comparison